Drug intelligence / Profile preview

NVKP-16

Development stage: Preclinical
Lead developer: KINETO Lab
Modality: Small Molecules

Overview

NVKP-16 is a small-molecule drug candidate developed by KINETO Lab designed to target RAS and KRAS mutations. The program focuses on addressing RASopathies and various KRAS-mutant cancers, including colon/rectal cancer, lung adenocarcinoma, and pancreatic cancer. Preclinical development for this program was conducted between 2016 and 2019. The drug aims to inhibit oncogenic signaling driven by RAS/KRAS mutations, which are prevalent in a high percentage of gastrointestinal and lung malignancies.

Other names: KRAS targeting (NVKP-16)

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)HRAS (H-Ras protein)

Beyond the preview

Go deeper on NVKP-16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVKP-16.

Explore the full profile